“Cemiplimab Improves Health-Related Quality of Life (HRQoL) and Reduces Pain in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Results from a Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial” (2021) SKIN The Journal of Cutaneous Medicine, 5(1), p. s5. doi:10.25251/skin.5.supp.5.